Danaher (NYSE:DHR) Stock Price Expected to Rise, Barclays Analyst Says

Danaher (NYSE:DHR) had its price target lifted by Barclays from $230.00 to $255.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the conglomerate’s stock. Barclays‘s price objective would indicate a potential upside of 17.57% from the stock’s current price.

A number of other research firms have also weighed in on DHR. Royal Bank Of Canada increased their price objective on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday. UBS Group started coverage on shares of Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target for the company. Guggenheim increased their price target on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $235.23.

Danaher Trading Up 0.6%

Shares of NYSE:DHR traded up $1.29 on Wednesday, reaching $216.90. 426,304 shares of the company traded hands, compared to its average volume of 4,439,927. The business’s 50-day simple moving average is $210.01 and its 200 day simple moving average is $194.05. Danaher has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a market capitalization of $152.48 billion, a P/E ratio of 38.37, a price-to-earnings-growth ratio of 2.75 and a beta of 0.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the company posted $0.77 EPS. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, equities analysts anticipate that Danaher will post 8.53 EPS for the current fiscal year.

Institutional Trading of Danaher

Several large investors have recently added to or reduced their stakes in DHR. Congress Asset Management Co. bought a new position in Danaher in the 3rd quarter worth $3,582,000. Moody National Bank Trust Division boosted its stake in shares of Danaher by 14.5% during the 3rd quarter. Moody National Bank Trust Division now owns 7,993 shares of the conglomerate’s stock valued at $1,771,000 after purchasing an additional 1,015 shares in the last quarter. RVW Wealth LLC bought a new stake in shares of Danaher during the 3rd quarter valued at about $4,118,000. Colton Groome Financial Advisors LLC purchased a new position in shares of Danaher during the third quarter valued at about $592,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in shares of Danaher during the third quarter valued at about $1,853,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.